PATENT COOPERATION TRE/ "Y

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING TRANSMITTAL OF COPY OF INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (CHAPTER I OF THE PATENT COOPERATION TREATY)

(PCT Rule 44bis.1(c))

To

MYERS BIGEL SIBLEY & SAJOVEC, P.A. P.O. Box 37428
Raleigh, North Carolina 27627
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)
18 October 2007 (18.10.2007)

Applicant's or agent's file reference 5470.398.WO

IMPORTANT NOTICE

International application No. PCT/US2004/030987

International filing date (day/month/year) 21 September 2004 (21.09.2004)

Priority date (day/month/year)
22 September 2003 (22.09.2003)

Applicant

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

10

2:14 IN

10-25-07 A09:14 IN

DOCKETED

By <u>50</u>

Date <u>10/25</u>

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Beate Giffo-Schmitt

Facsimile No. +41 22 338 82 70

e-mail: pt03.pct@wipo.int

PATENT COOPERATION TREAT.

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 5470.398.WO	FOR FURTHER ACTION	See item 4 below		
International application No. PCT/US2004/030987	International filing date (day/month/year) 21 September 2004 (21.09.2004)	Priority date (day/month/year) 22 September 2003 (22.09.2003)		
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237				
Applicant UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL				

NO before constitution to the constitution of					
1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 <i>bis</i> .1(a).				
2.	This REPORT consists of a total of 5 sheets, including this cover sheet.				
accopació al celevato	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.				
3.	3. This report contains indications relating to the following items:				
	Box No. I	Basis of the report			
	Box No. II	Priority			
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
	Box No. IV	Lack of unity of invention			
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
	Box No. VI	Certain documents cited			
	Box No. VII	Certain defects in the international application			
	Box No. VIII	Certain observations on the international application			
4.	The International Bureau will conot, except where the applicant date (Rule 44bis .2).	ommunicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but makes an express request under Article 23(2), before the expiration of 30 months from the priority			
		Date of issuance of this report			
		09 October 2007 (09.10.2007)			

Authorized officer

e-mail: pt03.pct@wipo.int

Beate Giffo-Schmitt

Facsimile No. +41 22 338 82 70 Form PCT/IB/373 (January 2004)

The International Bureau of WIPO 34, chemin des Colombettes

1211 Geneva 20, Switzerland

PATENT COOPERATION TREATY

From the INTERNAT	TIONAL SEARC	HING AUTHORIT	Y		
To: KAREN A. MAGRI MYERS BIGEL SIBLEY & SAJOVEC. P.A. P.O. BOX 37428 RALEIGH, NC 27627		PCT			
		WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY			
					(PCT Rule 43bis.1)
		Date of mailing 25 SEP 2007			
Applicant	's or agent's file r	eference		FOR FURTHER ACTION	
5470.398.	.wo			See paragraph 2 below	
Internation	nal application No	o. Inte	rnational filing date	(day/month/year) Priority date (day/month/year)	
PCT/US0		21.5	September 2004 (21.	09.2004)	22 September 2003 (22.09.2003)
Internation	nal Patent Classifi	ication (IPC) or both	national classificat	ion and IPC	
	C12Q 1/56(2006	5.01)			
USPC: Applicant	435/13				
UNIV. OF	NORTH CARO	LINA AT CHAPEI	HILL		
1. This o	opinion contains i	ndications relating t	o the following item	ıs:	
\boxtimes	Box No. I	Basis of the opini	on		
Box No. II Priority					
	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
	Box No. IV	Lack of unity of invention			
\bowtie	Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
	Box No. VI Certain documents cited				
	Box No. VII	Certain defects in	the international app	plication	
	Box No. VIII	Certain observation	ons on the internation	nal application	
2. FUR	THER ACTIO	N ·			
Intern Autho	ational Prelimina crity other than th	ry Examining Aut is one to be the IP	hority ("IPEA") ex	cept that this does IPEA has notified to	be considered to be a written opinion of the s not apply where the applicant chooses an he International Bureau under Rule 66.1bis(b) lered.
IPEA	a written reply to	gether, where appre	opriate, with amenda	ments, before the ex	PEA, the applicant is invited to submit to the correction of 3 months from the date of mailing whichever expires later.
		Form PCT/ISA/220		- •	-
3. For fu	rther details, see r	notes to Form PCT/I	SA/220.		
	mailing address of		Date of complet	ion of this opinion	Authorized officer
	Aail Stop PCT, Attn Commissioner for Pa		04 August 2007	·	Satyendra K. Singa Ulla College
P	O. Box 1450		VT August 2007	(04.00.2007)	,
Alexandria, Virginia 22313-1450			Telephone No. 571-272-8790		

Facsimile No. (571) 273-3201
Form PCT/ISA/237 (cover sheet) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/30987

Box No. I Basis of this opinion				
1. With regard to the language, this opinion has been established on the basis of:				
\boxtimes	the international application in the language in which it was filed			
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).			
2. With re inventi-	gard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed on, this opinion has been established on the basis of:			
a.	type of material			
	a sequence listing			
	table(s) related to the sequence listing			
b.	format of material			
	on paper			
	in electronic form			
c.	time of filing/furnishing			
	contained in the international application as filed.			
	filed together with the international application in electronic form.			
	furnished subsequently to this Authority for the purposes of search.			
	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.			
4. Additio	nal comments:			

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/30987

Box No. II Priority				
1.	The validity of the priority claim has not been considered because the International Searching Authority does not have in its possession a copy of the earlier application whose priority has been claimed or, where required, a translation of that earlier application. This opinion has nevertheless been established on the assumption that the relevant date (Rules 43bis.1 and 64.1) is the claimed priority date.			
2.	This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.			
This ir	al observations, if necessary: nternational search authority acknowledges applicant's claim for priority over US provisional application US 60504796 filed or otember 2003.			

Form PCT/ISA/237 (Box No. II) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/30987

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
1. Statement			
Novelty (N)	Claims 3-49	YES	
	Claims 1-2	NO	
Inventive step (IS)	Claims NONE	YES	
	Claims 1-49	NO	
Industrial applicability (IA)	Claims 1-49	YES	
	Claims NONE	NO	

2. Citations and explanations:

Claims 1 and 2 lack novelty under PCT Article 33(2) as being anticipated by Triplett et al (US 5,705,198). Triplett et al disclose a method of evaluating clotting activity comprising: combining a plasma sample (from patients containing lupus anticoagulant, LA; see Triplett et al, abstract, summary of the invention, examples 4 and 5, in particular), a soluble phospholipid (see Triplett et al, column 5, 4th paragraph, in particular), a contact activator and calcium chloride (see Chromogenic Test for thrombin activity, example 5, in particular), incubating said mixture for a time and under conditions sufficient for thrombin activation, and detecting thrombin activity (by the release of p-nitroaniline that is measured photometrically) which is indicative of clotting factor activity in the sample.

Claims 1-49 lack an inventive step under PCT Article 33(3) as being obvious over the following prior art cited by the Examiner: Triplett et al (US 5,705,198); Speck (US 3,486,981); Matschiner (US 5,525,478); Kraus (US 2002/0019021 A1); Rosen et al (US 6,395,501 B1); Dai et al (US 2003/0073071 A1); and Wang et al (US 6,596,543 B2).

Claims are generally directed to various methods (including a composition, and a kit) of evaluating clotting activity, or clotting time based on thrombin or clotting factor activity in blood or plasma samples. The prior art relied upon by the Examiner discloses a generic method (as discussed above, Triplett et al) for evaluating the clotting activity of blood or plasma from patient sample. In addition, various components used in the method, such as contact activator (see Speck, columns 3-4; uses ellagic acid; Rosen et al, see claims 26-27, in particular), activated protein C or APC and protein S depleted plasma, various phospholipids, tissue factor and other clotting factors, various standards and controls, and kits comprising said reagents for performing said clotting assay (see Matschiner, abstract, figures 1-4, examples; Kraus, abstract, pages 3-4, page 5 [0051]; Rosen et al, abstract, columns 7-9 and 10-12, examples and claims; Dai et al, abstract, example 5 and claims; and Wang et al, abstract, column 2-3, in particular) have been fully disclosed in the cited prior art. Therefore, it would have been obvious to a person of ordinary skill in the art to modify the methods of Triplett et al or Speck using/substituting the components already known in the art to arrive at the invention (methods as well as a composition and a kit) as claimed with a reasonable expectation of success. Thus, the entire invention as claimed lacks an inventive step.

Claims 1-49 meet the criteria set out in PCT Article 33(4), and thus claims 1-49 have industrial applicability because the subject matter claimed can be made or used in industry.

Form PCT/ISA/237 (Box No. V) (April 2005)